(NASDAQ: APRE) Aprea Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.6%.
Aprea Therapeutics's earnings in 2025 is -$13,038,738.On average, 4 Wall Street analysts forecast APRE's earnings for 2025 to be -$9,761,349, with the lowest APRE earnings forecast at -$14,347,946, and the highest APRE earnings forecast at -$4,724,801. On average, 4 Wall Street analysts forecast APRE's earnings for 2026 to be -$8,625,428, with the lowest APRE earnings forecast at -$13,172,899, and the highest APRE earnings forecast at -$3,644,414.
In 2027, APRE is forecast to generate -$3,250,628 in earnings, with the lowest earnings forecast at -$8,287,176 and the highest earnings forecast at $2,186,648.